Yueming He*1,
Wang Sheng†1,
Weiguo Hu‡1,
Jing Lin§, Junjun Liu§, Bing Yu§,
Xinru Mao§, Lu Zhang§, Jin Huang¶, Guangsuo Wang#
Oncology Research, Vol.27, No.8, pp. 901-910, 2019, DOI:10.3727/096504019X15509372008132
Abstract ROS1 rearrangements define a distinct molecular subset of non-small-cell lung cancer (NSCLC), which can be
treated effectively with crizotinib, a tyrosine kinase inhibitor (TKI) targeting ROS1/MET/ALK rearrangements.
Diverse efficacy was observed in ROS1-rearranged NSCLC patients. Because of its rareness, very limited
studies have investigated the correlation between different fusion partners and response to crizotinib. In this
study, we retrospectively screened 6,235 advanced NSCLC patients (stage IIIB to IV) from five hospitals and
identified 106 patients with ROS1 rearrangements based on either plasma or tumor tissue testing using capturebased targeted sequencing. The most frequently occurring fusion partners included cluster of differentiation… More >
Login
Register
